Premium
S5‐02–01: Predictors of Alzheimer's disease in subjects with mild cognitive impairment
Author(s) -
Visser Pieter J.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.565
Subject(s) - cognitive decline , dementia , medicine , memory clinic , atrophy , cognition , boston naming test , alzheimer's disease , psychology , disease , psychiatry
apy for slowing cognitive decline in AD. This trial found no benefit of B-vitamin therapy, despite significant Hcy reduction. These results are consistent with other recenly completed trials that studied cognitive outcomes in elderly, non-demented individuals. Ongoing studies in animal models have identified novel molecular mechanisms that may explain the association between elevated Hcy, particularly the finding that Hcy elevations are a marker of disturbed methylation of proteins, DNA, and other molecules. In addition, Hcy is associated with oxidative stress, and Bvitamin supplements in the face of oxidative stress may be ineffective in correcting the presumptive metabolic defect. This new mechanistic information may explain the failure of RCTs of high-dose B-vitamin therapy, and suggests new areas for clinical research designed to elucidate the role of Hcy in aging and neurodegenerative disease. Conclusions: Despite disappointing results of recently completed RCTs, there remains substantial interest in studies designed to establish a possible role of Hcy-lowering therapy in aging and neurodegenerative disease. The next generation of clinical research in this area will incorporate new insights from preclinical models and human observations. Supported by NIH R01AG17861, AA ZEN-06-27450.